Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal for Immunotherapy of Cancer
|
July 19, 2022
Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy
Philip C Simister, Ellen C Border, João F Vieira, et al.
Oncoimmunology
|
February 5, 2019
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
Ellen C Border, Joseph P Sanderson, Thomas Weissensteiner, et al.
Plos Pathogens
|
December 15, 2023
Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells
Yuqi Zhou, Julie Jadlowsky, Caitlin Baiduc, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 20, 2007
Human TCR-binding affinity is governed by MHC class restriction
David K Cole, Nicholas J Pumphrey, Jonathan M Boulter, et al.
European Journal of Immunology
|
September 30, 2011
Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d binding
Joseph P Sanderson, Kathrin Waldburger-Hauri, Diana Garzón, et al.
Hepatology (Baltimore, Md.)
|
December 19, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer
Roslin Y Docta, Tiago Ferronha, Joseph P Sanderson, et al.
Plos One
|
April 4, 2024
Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin
Martyn J Hiscox, Alexandra Wasmuth, Chris L Williams, et al.
Protein & Cell
|
January 8, 2011
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation
Ruth K Moysey, Yi Li, Samantha J Paston, et al.
Science Translational Medicine
|
August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
Brian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Nature Medicine
|
May 8, 2012
Monoclonal TCR-redirected tumor cell killing
Nathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal for Immunotherapy of Cancer
|
July 19, 2022
Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy
Philip C Simister, Ellen C Border, João F Vieira, et al.
Oncoimmunology
|
February 5, 2019
Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate
Ellen C Border, Joseph P Sanderson, Thomas Weissensteiner, et al.
Plos Pathogens
|
December 15, 2023
Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells
Yuqi Zhou, Julie Jadlowsky, Caitlin Baiduc, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 20, 2007
Human TCR-binding affinity is governed by MHC class restriction
David K Cole, Nicholas J Pumphrey, Jonathan M Boulter, et al.
European Journal of Immunology
|
September 30, 2011
Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d binding
Joseph P Sanderson, Kathrin Waldburger-Hauri, Diana Garzón, et al.
Hepatology (Baltimore, Md.)
|
December 19, 2018
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer
Roslin Y Docta, Tiago Ferronha, Joseph P Sanderson, et al.
Plos One
|
April 4, 2024
Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin
Martyn J Hiscox, Alexandra Wasmuth, Chris L Williams, et al.
Protein & Cell
|
January 8, 2011
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation
Ruth K Moysey, Yi Li, Samantha J Paston, et al.
Science Translational Medicine
|
August 9, 2013
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells
Brian J Cameron, Andrew B Gerry, Joseph Dukes, et al.
Nature Medicine
|
May 8, 2012
Monoclonal TCR-redirected tumor cell killing
Nathaniel Liddy, Giovanna Bossi, Katherine J Adams, et al.
Page
of 2